<?xml version="1.0" encoding="UTF-8"?>
<databaseChangeLog
        xmlns="http://www.liquibase.org/xml/ns/dbchangelog"
        xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
        xsi:schemaLocation="http://www.liquibase.org/xml/ns/dbchangelog
 http://www.liquibase.org/xml/ns/dbchangelog/dbchangelog-3.1.xsd">

    <changeSet id="ENG-6333-01" author="mdaly">
        <comment>Add column for the template lookup codes. Add column for ordering subtemplates.</comment>
        <sql>
            ALTER TABLE `prodlims`.`HorizonDiseaseResultTemplate` ADD COLUMN `lookupCode` VARCHAR(200) NOT NULL AFTER `associatedCall_id`;
            ALTER TABLE `prodlims`.`HorizonDiseaseResultTemplate_HorizonDiseaseResultTemplate` ADD COLUMN `processingOrder` INTEGER NOT NULL AFTER `subtemplates_id`;
        </sql>

        <rollback>
            ALTER TABLE `prodlims`.`HorizonDiseaseResultTemplate` DROP COLUMN `lookupCode`;
            ALTER TABLE `prodlims`.`HorizonDiseaseResultTemplate_HorizonDiseaseResultTemplate` DROP COLUMN `processingOrder`;
        </rollback>
    </changeSet>

    <changeSet id="ENG-6333-02" author="mdaly">
        <comment>Add new disease for Tay-Sachs when there is combined DNA and TSE order.</comment>
        <sql>
            INSERT INTO `prodlims`.`horizondisease`
            (`name`, `mutation`, `refSeqNumber`, `provider`, `inheritancePattern`, `ce_id`, `ce_text`, `ce_system`, `cloudid`)
            VALUES
            ('Tay-Sachs Disease (DNA and enzyme)', 'HEXA', '(NM_000520.4)', 'NATERA_LAB', 'AUTOSOMAL_RECESSIVE', '50258', 'Tay-Sachs Disease (DNA only)', 'L', 'TSCOMBO');
        </sql>

        <rollback>
            SET SQL_SAFE_UPDATES=0;
            DELETE FROM `prodlims`.`horizondisease` WHERE `cloudid` = 'TSCOMBO';
            SET SQL_SAFE_UPDATES=1;
        </rollback>
    </changeSet>

    <changeSet id="ENG-6333-03" author="mdaly">
        <comment>Delete any existing ResultCalls and DiseaseResultTemplates and load up the newer ones.</comment>
        <sql>
            SET SQL_SAFE_UPDATES=0;
            SET FOREIGN_KEY_CHECKS=0;

            DELETE FROM `prodlims`.`horizonresultcall`;
            DELETE FROM `prodlims`.`HorizonDiseaseResultTemplate`;
            DELETE FROM `prodlims`.`HorizonDiseaseResultTemplate_HorizonDiseaseResultTemplate`;

            INSERT INTO `prodlims`.`horizonresultcall`
            (`id`, `resulttype`, `description`, `cloudIdentifier`)
            VALUES
            (1, 'OTHER', 'Unknown', NULL),
            (2, 'NEGATIVE', 'Negative', 'NEGATIVE'),
            (3, 'OTHER', 'Other', 'OTHER'),
            (4, 'TEST_NOT_PERFORMED', 'Test Not Performed', 'TNP'),
            (5, 'TEST_NOT_PERFORMED_REDRAW_RECOMMENDED', 'Test Not Performed (Redraw Recommended)', NULL),
            (6, 'POSITIVE', 'Pathogenic variant', 'PATHOGENIC'),
            (7, 'POSITIVE', 'Likely pathogenic variant', 'LIKELY_PATHOGENIC'),
            (8, 'POSITIVE', '2 variants detected', NULL),
            (9, 'POSITIVE', '3 variants detected', NULL),
            (10, 'POSITIVE', '45-54 CGG repeats', 'INT_NEGATIVE'),
            (11, 'POSITIVE', '55-90 CGG repeats', 'PREMUT_55_90_NEGATIVE'),
            (12, 'POSITIVE', '91-200 CGG repeats', 'PREMUT_91_200_NEGATIVE'),
            (13, 'POSITIVE', '>200 CGG repeats', 'FULLMUT_NEGATIVE'),
            (14, 'POSITIVE', '>Two CGG alleles detected, one allele intermediate (45-54)', NULL),
            (15, 'POSITIVE', '>Two CGG alleles detected, one allele premutation (55-90 repeats)', NULL),
            (16, 'POSITIVE', '>Two CGG alleles detected, one allele premutation (91-200 repeats)', NULL),
            (17, 'POSITIVE', 'One allele intermediate (45-54) and one allele premutation (55-90)', 'PREMUT_55_90_INT'),
            (18, 'POSITIVE', 'One allele intermediate (45-54) and one allele premutation (91-200)', 'PREMUT_91_200_INT'),
            (19, 'POSITIVE', 'Two alleles intermediate (45-54)', 'INT_BOTH'),
            (20, 'POSITIVE', 'Two alleles premutation (55-90)', 'PREMUT_55_90_BOTH'),
            (21, 'POSITIVE', 'One premutation 55-90 CGG and one premutation 91-200 CGG', 'PREMUT_55_90_PREMUT_91_200'),
            (22, 'POSITIVE', 'Two alleles premutation (91-200)', 'PREMUT_91_200_BOTH'),
            (23, 'NEGATIVE', 'Normal', 'NORMAL'),
            (24, 'POSITIVE', 'Pathogenic deletion', 'PATHOGENIC_DELETION'),
            (25, 'POSITIVE', 'Pathogenic duplication', 'PATHOGENIC_DUPLICATION'),
            (26, 'POSITIVE', 'Likely pathogenic deletion', 'LIKELY_PATHOGENIC_DELETION'),
            (27, 'POSITIVE', 'Likely pathogenic duplication', 'LIKELY_PATHOGENIC_DUPLICATION'),
            (28, 'POSITIVE', 'SMN1: 0 copies', 'NO_COPY'),
            (29, 'POSITIVE', 'SMN1: 1 copy', 'ONE_COPY'),
            (30, 'OTHER', 'SMN1: 2 copies', 'TWO_COPIES'),
            (31, 'NEGATIVE', 'SMN1: 3 or more copies', 'THREE_OR_MORE_COPIES'),
            (32, 'POSITIVE', 'Positive Enzyme', 'POSITIVE'),
            (33, 'POSITIVE', 'Indetermindate Enzyme', 'INDETERMINATE'),
            (34, 'OTHER', 'Possible Sandhoff', 'POSSIBLE_SANDHOFF_ELEVATED'),
            (35, 'POSITIVE', 'Heterozygous Deletion', 'HETEROZYGOUS_DELETION'),
            (36, 'POSITIVE', 'Heterozygous Duplication', 'HETEROZYGOUS_DUPLICATION'),
            (37, 'POSITIVE', 'Homozygous Deletion', 'HOMOZYGOUS_DELETION'),
            (38, 'POSITIVE', 'Homozygous Duplication', 'HOMOZYGOUS_DUPLICATION'),
            (39, 'POSITIVE', '0 copies of the SMN1 gene; g.27134T>G present', NULL),
            (40, 'POSITIVE', '0 copies of the SMN1 gene; g.27134T>G absent', NULL),
            (41, 'POSITIVE', '1 copy of the SMN1 gene; g.27134T>G present', NULL),
            (42, 'POSITIVE', '1 copy of the SMN1 gene; g.27134T>G absent', NULL),
            (43, 'POSITIVE', '2 copies of the SMN1 gene; g.27134T>G present and Jewish or Asian ethnicity reported', NULL),
            (44, 'POSITIVE', '2 copies of the SMN1 gene; g.27134T>G present and Caucasian ethnicity reported', NULL),
            (45, 'POSITIVE', '2 copies of the SMN1 gene; g.27134T>G present and African-American ethnicity reported', NULL),
            (46, 'POSITIVE', '2 copies of the SMN1 gene; g.27134T>G present and Hispanic ethnicity reported', NULL),
            (47, 'POSITIVE', '2 copies of the SMN1 gene; g.27134T>G present and no ethnicity reported', NULL),
            (48, 'NEGATIVE', '2 copies of the SMN1 gene; g.27134T>G absent', NULL),
            (49, 'NEGATIVE', '3 or more copies of the SMN1 gene; g.27134T>G present', NULL),
            (50, 'NEGATIVE', '3 or more copies of the SMN1 gene; g.27134T>G absent', NULL);

            INSERT INTO `prodlims`.`HorizonDiseaseResultTemplate`
            (`id`,`associatedCall_id`,`lookupCode`, `label`,`headLine`,`clinicalDetails`)
            VALUES
            (1, 2, 'NEGATIVE', 'Negative', 'NEGATIVE for ${diseaseName}', ''),
            (2, 3, 'OTHER', 'Other', '', ''),
            (3, 4, 'TNP', 'Test Not Performed', 'Test Not Performed for ${diseaseName}', ''),
            (4, 5, 'TNP_REDRAW', 'Test Not Performed, Redraw Requested', 'Test Not Performed for ${diseaseName}', ''),
            (5, 6, 'ACADM_c.683C>A', 'c.683C>A (p.T228N)', 'CARRIER for ${diseaseName}', 'Positive for the pathogenic variant c.683C>A (p.T228N) in the ACADM gene. This variant is associated with an atypical presentation (PMID 15171998, 20434380). If this individual''s partner is a carrier for ${diseaseName}, their chance to have a child with this condition may be as high as 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (6, 7, 'ASS1_c.257G>A', 'c.257G>A (p.R86H)', 'CARRIER for ${diseaseName}', 'Positive for the likely pathogenic variant c.257G>A (p.R86H) in the ASS1 gene. This variant is associated with a mild presentation (PMID 12815590). If this individual''s partner is a carrier for ${diseaseName}, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (7, 6, 'CFTR_c.3454G>C', 'c.3454G>C (p.D1152H)', 'CARRIER for ${diseaseName}', 'Positive for the pathogenic variant c.3454G>C (p.D1152H) in the CFTR gene. This variant is associated with an atypical presentation and has varying consequences. Some individuals with this variant, along with another CFTR pathogenic variant, have Cystic Fibrosis, while some individuals do not (PMID 23974870). If this individual''s partner is a carrier for ${diseaseName}, their chance to have a child with this condition may be as high as 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (8, 7, 'GALT_DUARTE', 'One Duarte variant detected', 'Duarte VARIANT DETECTED for ${diseaseName}', 'The Duarte variant ${results[0].variantName} was detected in the GALT gene. If this individual''s partner is a carrier for ${diseaseName}, their chance to have a child with Duarte variant Galactosemia is 1 in 4 (25%). Duarte variant Galactosemia may have mild or no clinical effects. Carrier screening for this individual''s partner is suggested.'),
            (9, 7, 'HBB_c.208G>A', 'c.208G>A (p.G70S) (Hb City of Hope)', 'CARRIER for Beta-Thalassemia', 'Positive for the likely pathogenic variant c.208G>A (p.G70S) (Hb City of Hope) in the HBB gene. This variant has been reported to cause a thalassemia phenotype when found in trans with beta (0) variants and has also been reported to cause disease when identified in trans with HbS (PMID: 2467892, 25113778, 21302591). Carriers of this variant do not display any hematological manifestations of beta-thalassemia and have normal CBC and hemoglobin electrophoresis. Beta-thalassemia individuals who are homozygous for this variant have not been reported in the literature; therefore, this variant may not cause a disease phenotype when homozygous. If this individual''s partner is a carrier for Beta-Thalassemia or Beta-Hemoglobinopathy, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (10, 7, 'SMPD1_c.1474G>A', 'c.1474G>A (p.G492S)', 'CARRIER for Niemann-Pick Disease, Type B', 'Positive for the likely pathogenic variant c.1474G>A (p.G492S) in the SMPD1 gene. This variant is associated with mild Niemann-Pick type B (PMID 23252888). If this individual''s partner is a carrier for ${diseaseName}, their chance to have a child with this condition may be as high as 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (11, 6, 'SMPD1_c.995C>G', 'c.995C>G (p.P332R)', 'CARRIER for ${diseaseName}', 'Positive for the pathogenic variant c.995C>G (p.P332R) in the SMPD1 gene. This variant is associated with a mild presentation (PMID 15545621). If this individual''s partner is a carrier for ${diseaseName}, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (12, 6, 'PATHOGENIC', 'Pathogenic variant detected', 'CARRIER for ${diseaseName}', 'Positive for the pathogenic variant ${results[0].variantName} in the ${gene} gene. If this individual''s partner is a carrier for ${diseaseName} their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (13, 7, 'LIKELY_PATHOGENIC', 'Likely pathogenic variant detected', 'CARRIER for ${diseaseName}', 'Positive for the likely pathogenic variant ${results[0].variantName} in the ${gene} gene. If this individual''s partner is a carrier for ${diseaseName}, their chance to have a child with this condition may be as high as 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (14, 8, 'TWO_UNKNOWN', 'Two variants detected (cis or trans unknown)', 'POSITIVE for two variants in the gene associated with ${diseaseName}', 'Positive for the ${results[0].type} variant ${results[0].variantName} and ${results[1].type} variant ${results[1].variantName} in the ${gene} gene. This individual may be affected with ${diseaseName}. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. This analysis cannot determine if the ${gene} variants are on the same (in cis) or opposite (in trans) chromosomes in this individual. Testing of parents or other close family members may assist in determining the phase of these variants. If this individual''s partner is a carrier for ${diseaseName}, their chance to have a child with this condition may be as high as 1 in 2 (50%). Carrier screening for this individual''s partner is suggested.'),
            (15, 8, 'TWO_CIS', 'Two variants detected (cis)', 'CARRIER for ${diseaseName}', 'Positive for the ${results[0].type} variant ${results[0].variantName} and ${results[1].type} variant ${results[1].variantName} in cis (on the same chromosome) in the ${gene} gene. If this individual''s partner is a carrier for ${diseaseName}, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (16, 8, 'TWO_TRANS', 'Two variants detected (trans)', 'POSITIVE for two variants in the gene associated with ${diseaseName}', 'Positive for the ${results[0].type} variant ${results[0].variantName} and ${results[1].type} variant ${results[1].variantName} in the ${gene} gene. This individual is predicted to be affected with ${diseaseName}. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. If this individual''s partner is a carrier for ${diseaseName}, their chance to have a child with this condition may be as high as 1 in 2 (50%). Carrier screening for this individual''s partner is suggested.'),
            (17, 6, 'PATHOGENIC', 'Pathogenic variant detected', 'CARRIER for ${diseaseName}', 'Positive for the pathogenic variant ${results[0].variantName} in the ${gene} gene. Female carriers may experience some symptoms of this condition. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. Each of the patient''s sons has a 50% chance of being affected and each of her daughters has a 50% chance of being a carrier.'),
            (18, 7, 'LIKELY_PATHOGENIC', 'Likely pathogenic variant detected', 'CARRIER for ${diseaseName}', 'Positive for the likely pathogenic variant ${results[0].variantName} in the ${gene} gene. Female carriers may experience some symptoms of this condition. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. Each of the patient''s sons has up to a 50% chance of being affected and each of her daughters has up to a 50% chance of being a carrier.'),
            (19, 8, 'TWO_UNKNOWN', 'Two variants detected (cis or trans unknown)', 'POSITIVE for two variants in the gene associated with ${diseaseName}', 'Positive for the ${results[0].type} variant ${results[0].variantName} and ${results[1].type} variant ${results[1].variantName} in the ${gene} gene. This individual may be affected with ${diseaseName}. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. This analysis cannot determine if the ${gene} variants are on the same (in cis) or opposite (in trans) chromosomes in this individual. Testing of parents or other close family members may assist in determining the phase of these variants. Each of this individual''s sons has up to a 100% chance of being affected and each of her daughters has up to a 100% chance of being a carrier.'),
            (20, 8, 'TWO_CIS', 'Two variants detected (cis)', 'CARRIER for ${diseaseName}', 'Positive for the ${results[0].type} variant ${results[0].variantName} and ${results[1].type} variant ${results[1].variantName} in cis (on the same chromosome) in the ${gene} gene. Female carriers may experience some symptoms of this condition. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. Each of this individual''s sons has a 50% chance of being affected and each of her daughters has a 50% chance of being a carrier.'),
            (21, 8, 'TWO_TRANS', 'Two variants detected (trans)', 'POSITIVE for two variants in the gene associated with ${diseaseName}', 'Positive for the ${results[0].type} variant ${results[0].variantName} and ${results[1].type} variant ${results[1].variantName} in the ${gene} gene. This individual is predicted to be affected with ${diseaseName}. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. Each of this individual''s sons has a 100% chance of being affected and each of her daughters has a 100% chance of being a carrier.'),
            (22, 9, 'THREE', 'Three variants detected', 'POSITIVE for multiple variants in the gene associated with ${diseaseName}', ''),
            (23, 2, 'NEGATIVE', 'Negative', 'NEGATIVE ${diseaseName} results', 'CGG repeats were detected in the FMR1 genes.'),
            (24, 2, 'NEGATIVE_THREE', 'Negative; three alleles detected; CGG repeats normal', 'NEGATIVE ${diseaseName} results', 'Three normal FMR1 CGG repeat sizes were detected: ${(results[0].cggRepeats[0])!"cgg1"}, ${(results[0].cggRepeats[1])!"cgg2"}, and ${(results[0].cggRepeats[2])!"cgg3"}. The presence of three alleles may be due to X chromosome aneuploidy, a duplication on the X chromosome, a somatic change in one of the alleles, or an assay artifact. Karyotype and/or chromosomal microarray can be considered to clarify these results.'),
            (25, 2, 'NEGATIVE_THREE_MINOR', 'Negative; three alleles detected; CGG repeats normal, one allele minor', 'NEGATIVE ${diseaseName} results', 'Three normal FMR1 CGG repeat sizes were detected: ${(results[0].cggRepeats[0])!"cgg1"}, ${(results[0].cggRepeats[1])!"cgg2"}, and ${(results[0].cggRepeats[2])!"cgg3"} (minor allele). The presence of three alleles may be due to X chromosome aneuploidy, a duplication on the X chromosome, a somatic change in one of the alleles, or an assay artifact. Karyotype and/or chromosomal microarray can be considered to clarify these results.'),
            (26, 10, 'INT_NEG', '45-54 CGG repeats', 'INTERMEDIATE ALLELE size detected for ${diseaseName}', 'An intermediate size ${(results[0].cggRepeats[0])!"cgg1"} CGG repeat allele and a normal size ${(results[0].cggRepeats[1])!"cgg2"} allele were detected in the FMR1 genes. This individual is not at increased risk to have a child with Fragile X Syndrome. In some cases, intermediate size repeat alleles can expand to a premutation (carrier status) in future generations. AGG testing through Asuragen Laboratories will be performed and a separate report will be sent. This report will refine the chance for expansion of the CGG repeat tract.'),
            (27, 11, 'PREMUT_LOW_NEG', '55-90 CGG repeats', 'PREMUTATION CARRIER for ${diseaseName}', 'POSITIVE for a premutation size ${(results[0].cggRepeats[0])!"cgg1"} CGG repeat allele and a normal size ${(results[0].cggRepeats[1])!"cgg2"} allele in the FMR1 genes. Female premutation carriers have an increased risk for Fragile X associated Primary Ovarian Insufficiency (POI) and up to a 17% risk to develop symptoms of a late-onset neurological condition called Fragile X associated Tremor/Ataxia Syndrome (FXTAS). Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. This individual is at increased risk to have a child with Fragile X Syndrome. AGG testing through Asuragen Laboratories will be performed and a separate report will be sent. This report will refine the chance for expansion of the CGG repeat tract.'),
            (28, 12, 'PREMUT_HIGH_NEG', '91-200 CGG repeats', 'PREMUTATION CARRIER for ${diseaseName}', 'POSITIVE for a premutation size ${(results[0].cggRepeats[0])!"cgg1"} CGG repeat allele and a normal size ${(results[0].cggRepeats[1])!"cgg2"} allele in the FMR1 genes. Female premutation carriers have an increased risk for Fragile X associated Primary Ovarian Insufficiency (POI) and up to a 17% risk to develop symptoms of a late-onset neurological condition called Fragile X associated Tremor/Ataxia Syndrome (FXTAS). Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. This individual is at increased risk to have a child with Fragile X Syndrome.'),
            (29, 13, 'MUT', '>200 CGG repeats', 'POSSIBLY AFFECTED with ${diseaseName}', 'POSITIVE for a >200 CGG repeat allele and a normal ${(results[0].cggRepeats[0])!"cgg1"} CGG repeat allele in the FMR1 genes. This individual has an increased chance to have some cognitive, behavioral and/or physical characteristics of Fragile X Syndrome. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. This individual has a 50% chance of passing on the expanded CGG allele.'),
            (30, 14, 'INT_TWO_PLUS', '>Two CGG alleles detected, one allele intermediate (45-54)', 'INTERMEDIATE ALLELE size detected for ${diseaseName}', 'An intermediate sized ${(results[0].cggRepeats[0])!"cgg1"} CGG repeat allele and a normal sized ${(results[0].cggRepeats[1])!"cgg2"} CGG repeat allele were detected in the FMR1 gene. An additional allele in the normal range with ${(results[0].cggRepeats[2])!"cgg3"} CGG repeats was also detected. The presence of three alleles in this individual''s sample may be due to X chromosome aneuploidy, a duplication on the X chromosome, a somatic change in one of the alleles, or a PCR artifact. Karyotype and/or chromosomal microarray may be considered to clarify these results. This individual is not at increased risk to have a child with Fragile X Syndrome. In some cases, intermediate size repeat alleles can expand to a premutation (carrier status) in future generations. AGG testing through Asuragen Laboratories will be performed and a separate report will be sent. This report will refine the chance for expansion of the CGG repeat tract.'),
            (31, 15, 'PREMUT_LOW_TWO_PLUS', '>Two CGG alleles detected, one allele premutation (55-90 repeats)', 'PREMUTATION CARRIER for ${diseaseName}', 'A premutation sized ${(results[0].cggRepeats[0])!"cgg1"} CGG repeat allele and a normal sized ${(results[0].cggRepeats[1])!"cgg2"} CGG repeat allele were detected in the FMR1 gene. An additional allele in the normal range with ${(results[0].cggRepeats[2])!"cgg3"} CGG repeats was also detected. The presence of three alleles in this individual''s sample may be due to X chromosome aneuploidy, a duplication on the X chromosome, a somatic change in one of the alleles, or an assay artifact. Karyotype and/or chromosomal microarray may be considered to clarify these results. Female premutation carriers have an increased risk for Fragile X associated Primary Ovarian Insufficiency (POI) and up to a 17% risk to develop symptoms of a late-onset neurological condition called Fragile X associated Tremor/Ataxia Syndrome (FXTAS). Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. This individual is at increased risk to have a child with Fragile X Syndrome. AGG testing through Asuragen Laboratories will be performed and a separate report will be sent. This report will refine the chance for expansion of the CGG repeat tract.'),
            (32, 16, 'PREMUT_HIGH_TWO_PLUS', '>Two CGG alleles detected, one allele premutation (91-200 repeats)', 'PREMUTATION CARRIER for ${diseaseName}', 'A premutation sized ${(results[0].cggRepeats[0])!"cgg1"} CGG repeat allele and a normal sized ${(results[0].cggRepeats[1])!"cgg2"} CGG repeat allele were detected in the FMR1 gene. An additional allele in the normal range with ${(results[0].cggRepeats[2])!"cgg3"} CGG repeats was also detected. The presence of three alleles in this individual''s sample may be due to X chromosome aneuploidy, a duplication on the X chromosome, a somatic change in one of the alleles, or an assay artifact. Karyotype and/or chromosomal microarray may be considered to clarify these results. Female premutation carriers have an increased risk for Fragile X associated Primary Ovarian Insufficiency (POI) and up to a 17% risk to develop symptoms of a late-onset neurological condition called Fragile X associated Tremor/Ataxia Syndrome (FXTAS). Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. This individual is at increased risk to have a child with Fragile X Syndrome.'),
            (33, 17, 'PREMUT_LOW_INT', 'One allele intermediate (45-54) and one allele premutation (55-90)', 'PREMUTATION CARRIER for ${diseaseName}', 'One premutation size ${(results[0].cggRepeats[0])!"cgg1"} and one intermediate size ${(results[0].cggRepeats[1])!"cgg2"} CGG repeat alleles were detected in the FMR1 gene. Female premutation carriers have an increased risk for Fragile X associated Primary Ovarian Insufficiency (POI) and up to a 17% risk to develop symptoms of a late-onset neurological condition called Fragile X associated Tremor/Ataxia Syndrome (FXTAS). Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. This individual is at increased risk to have a child with Fragile X Syndrome. AGG testing through Asuragen Laboratories will be performed and a separate report will be sent. This report will refine the chance for expansion of the CGG repeat tract.'),
            (34, 18, 'PREMUT_HIGH_INT', 'One allele intermediate (45-54) and one allele premutation (91-200)', 'PREMUTATION CARRIER for ${diseaseName}', 'One premutation size ${(results[0].cggRepeats[0])!"cgg1"} and one intermediate size ${(results[0].cggRepeats[1])!"cgg2"} CGG repeat alleles were detected in the FMR1 gene. Female premutation carriers have an increased risk for Fragile X associated Primary Ovarian Insufficiency (POI) and up to a 17% risk to develop symptoms of a late-onset neurological condition called Fragile X associated Tremor/Ataxia Syndrome (FXTAS). Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. This individual is at increased risk to have a child with Fragile X Syndrome.'),
            (35, 19, 'INT_INT', 'Two alleles intermediate (45-54)', 'INTERMEDIATE ALLELE sizes detected for ${diseaseName}', 'One intermediate size ${(results[0].cggRepeats[0])!"cgg1"} and one intermediate size ${(results[0].cggRepeats[1])!"cgg2"} CGG repeat alleles were detected in the FMR1 gene. This individual is not at increased risk to have a child with Fragile X Syndrome. In some cases, intermediate size repeat alleles can expand to a premutation (carrier status) in future generations. AGG testing through Asuragen Laboratories will be performed and a separate report will be sent. This report will refine the chance for expansion of the CGG repeat tract.'),
            (36, 20, 'PREMUT_LOW_PREMUT_LOW', 'Two alleles premutation (55-90)', 'PREMUTATION CARRIER for ${diseaseName}', 'Two premutation size ${(results[0].cggRepeats[0])!"cgg1"} and ${(results[0].cggRepeats[1])!"cgg2"} CGG repeat alleles were detected in the FMR1 gene. Female premutation carriers have an increased risk for Fragile X associated Primary Ovarian Insufficiency (POI) and a late-onset neurological condition called Fragile X associated Tremor/Ataxia Syndrome (FXTAS). Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. This individual is at increased risk to have a child with Fragile X Syndrome. AGG testing through Asuragen Laboratories will be performed and a separate report will be sent. This report will refine the chance for expansion of the CGG repeat tract.'),
            (37, 21, 'PREMUT_HIGH_PREMUT_LOW', 'One premutation 55-90 CGG and one premutation 91-200 CGG', 'PREMUTATION CARRIER for ${diseaseName}', 'Two premutation size ${(results[0].cggRepeats[0])!"cgg1"} and ${(results[0].cggRepeats[1])!"cgg2"} CGG repeat alleles were detected in the FMR1 gene. Female premutation carriers have an increased risk for Fragile X associated Primary Ovarian Insufficiency (POI) and a late-onset neurological condition called Fragile X associated Tremor/Ataxia Syndrome (FXTAS). Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. This individual is at increased risk to have a child with Fragile X Syndrome. AGG testing through Asuragen Laboratories will be performed and a separate report will be sent. This report will refine the chance for expansion of the CGG repeat tract.'),
            (38, 22, 'PREMUT_HIGH_PREMUT_HIGH', 'Two alleles premutation (91-200)', 'PREMUTATION CARRIER for ${diseaseName}', 'Two premutation size ${(results[0].cggRepeats[0])!"cgg1"} and ${(results[0].cggRepeats[1])!"cgg2"} CGG repeat alleles were detected in the FMR1 gene. Female premutation carriers have an increased risk for Fragile X associated Primary Ovarian Insufficiency (POI) and a late-onset neurological condition called Fragile X associated Tremor/Ataxia Syndrome (FXTAS). Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. This individual is at increased risk to have a child with Fragile X Syndrome.'),
            (39, 6, 'POINT', 'Point variant or indel detected', 'CARRIER for ${diseaseName}', 'Positive for the pathogenic variant ${results[0].variantName} in the FMR1 gene. Normal CGG repeats detected. ${(results[0].cggRepeats[0])!"cgg1"} and ${(results[0].cggRepeats[1])!"cgg2"} CGG repeats. The individual is at increased risk to have a child with Fragile X Syndrome.'),
            (40, 2, 'NEGATIVE_POLYT', 'No variants detected, polyT requested', 'NEGATIVE for Cystic Fibrosis', 'As requested by provider, ${"[polyT values]"} variants were detected in the PolyT tract of the CFTR gene pair.'),
            (41, 6, 'R117H_55', 'R117H variant and 5T/5T detected', 'CARRIER for Cystic Fibrosis', 'Positive for the pathogenic p.R117H variant and the 5T/5T variants in the CFTR gene. This individual has one copy of the 5T variant on the same chromosome (in cis) as the p.R117H variant and one copy on the opposite chromosome (in trans). The p.R117H variant in cis with a 5T variant is pathogenic and when present in trans with another pathogenic variant is causative for variable symptoms of Cystic Fibrosis. This individual may be asymptomatic or may have findings of Cystic Fibrosis such as congenital absence of the vas deferens, mild pulmonary symptoms, or idiopathic pancreatitis. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. If this individual''s partner is a carrier for Cystic Fibrosis, their chance to have a child with this condition is 1 in 4 (25%) and may be as high as 1 in 2 (50%) to have a child with Cystic Fibrosis related symptoms. Carrier screening for this individual''s partner is suggested.'),
            (42, 6, 'R117H_57', 'R117H variant and 5T/7T detected', 'CARRIER for Cystic Fibrosis or Cystic Fibrosis-Related Metabolic Syndrome', 'Positive for the pathogenic p.R117H variant and the 5T/7T variants in the CFTR gene. The laboratory is unable to determine whether the 5T variant in this individual is on the same (in cis) or opposite (in trans) chromosomes as the p.R117H mutation. Testing of parents or other close family members may assist in determining the phase of these variants. The p.R117H variant in cis with a 5T variant is pathogenic and when present in trans with another pathogenic variant is causative for variable symptoms of Cystic Fibrosis. The p.R117H variant in cis with a 7T variant and in trans with a pathogenic CFTR variant may cause no symptoms, male infertility, or symptoms of Cystic Fibrosis-Related Metabolic Syndrome (PMID 19914443). If this individual''s partner is a carrier for Cystic Fibrosis, their chance to have a child with this condition is 1 in 4 (25%) and may be as high as 1 in 2 (50%) to have a child with Cystic Fibrosis-related symptoms. Carrier screening for this individual''s partner is suggested.'),
            (43, 6, 'R117H_59', 'R117H variant and 5T/9T detected', 'POSSIBLE CARRIER for Cystic Fibrosis', 'Positive for the p.R117H variant and the 5T/9T variants in the CFTR gene. The laboratory is unable to determine whether the 5T variant in this individual is on the same (in cis) or opposite (in trans) chromosomes as the p.R117H mutation. Testing of parents or other close family members may assist in determining the phase of these variants. The p.R117H variant in cis with a 5T variant is pathogenic and when present in trans with another pathogenic variant is causative for variable symptoms of Cystic Fibrosis. The p.R117H variant in cis with a 9T and in trans with a pathogenic CFTR variant is not expected to cause Cystic Fibrosis symptoms. If this individual''s partner is a carrier for Cystic Fibrosis, their chance to have a child with this condition is as high as 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (44, 6, 'R117H_77', 'R117H variant and 7T/7T detected', 'CARRIER for Cystic Fibrosis-Related Metabolic Syndrome', 'Positive for the pathogenic p.R117H variant and the 7T/7T variants in the CFTR gene. This individual has one copy of the 7T variant on the same chromosome (in cis) as the p.R117H variant and one copy on the opposite chromosome (in trans). The p.R117H variant in cis with a 7T variant and in trans with a pathogenic CFTR variant may cause no symptoms, male infertility, or symptoms of Cystic Fibrosis-Related Metabolic Syndrome (PMID 19914443). If this individual''s partner is a carrier for Cystic Fibrosis, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (45, 6, 'R117H_79', 'R117H variant and 7T/9T detected', 'POSSIBLE CARRIER for Cystic Fibrosis-Related Metabolic Syndrome', 'Positive for the pathogenic p.R117H variant and the 7T/9T variants in the CFTR gene. The laboratory is unable to determine whether the 7T variant in this individual is on the same (in cis) or opposite (in trans) chromosomes as the p.R117H mutation. Testing of parents or other close family members may assist in determining the phase of these variants. The p.R117H variant in cis with a 7T variant and in trans with a pathogenic CFTR variant may cause no symptoms, male infertility, or symptoms of Cystic Fibrosis-Related Metabolic Syndrome (PMID 19914443). The p.R117H variant in cis with a 9T and in trans with a pathogenic CFTR variant is not expected to cause Cystic Fibrosis symptoms. If this individual''s partner is a carrier for Cystic Fibrosis, their chance to have a child with this condition may be as high as 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (46, 6, 'PATHOGENIC_POLYT', 'Pathogenic variant detected and polyT requested by provider', 'CARRIER for Cystic Fibrosis', 'Positive for the pathogenic variant ${results[0].variantName} in the CFTR gene. As requested by provider, the ${"[polyT values]"} variants were detected in the PolyT tract of the CFTR gene pair. If this individual''s partner is a carrier for Cystic Fibrosis, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (47, 6, 'PATHOGENIC', 'Pathogenic variant detected (Duchenne or Becker)', 'CARRIER for Duchenne/Becker Muscular Dystrophy', 'Positive for the pathogenic variant ${results[0].variantName} in the DMD gene. Female carriers are at an increased chance to develop cardiomyopathy or muscle weakness. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. Duchenne/Becker Muscular Dystrophy is an X-linked disorder. Each of this individual''s sons has a 50% chance of being affected and each of her daughters has a 50% chance of being a carrier.'),
            (48, 7, 'LIKELY_PATHOGENIC', 'Likely pathogenic variant detected (Duchenne or Becker)', 'CARRIER for Duchenne/Becker Muscular Dystrophy', 'Positive for the likely pathogenic variant ${results[0].variantName} in the DMD gene. Female carriers are at an increased chance to develop cardiomyopathy or muscle weakness. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. Duchenne/Becker Muscular Dystrophy is an X-linked disorder. Each of this individual''s sons has up to a 50% chance of being affected and each of her daughters has up to a 50% chance of being a carrier.'),
            (49, 6, 'PATHOGENIC_DMD_CARDIO', 'Pathogenic variant detected (DMD-Related Dilated Cardiomyopathy)', 'CARRIER for DMD-Related Dilated Cardiomyopathy', 'Positive for the pathogenic variant ${results[0].variantName} in the DMD gene. This variant is causative for DMD-Related Dilated Cardiomyopathy (DCM). DCM is a cardio-specific form of dystrophinopathy that results in heart failure without skeletal muscle weakness (PMID 26294044). Female carriers are at an increased chance to develop cardiomyopathy. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. DCM is an X-linked disorder. Each of this individual''s sons has a 50% chance of being affected and each of her daughters has a 50% chance of being a carrier.'),
            (50, 7, 'LIKELY_PATHOGENIC_DMD_CARDIO', 'Likely pathogenic variant detected (DMD-Related Dilated Cardiomyopathy)', 'CARRIER for DMD-Related Dilated Cardiomyopathy', 'Positive for the likely pathogenic variant ${results[0].variantName} in the DMD gene. This variant is likely causative for DMD-Related Dilated Cardiomyopathy (DCM). DCM is a cardio-specific form of dystrophinopathy that results in heart failure without skeletal muscle weakness (PMID 26294044). Female carriers are at an increased chance to develop cardiomyopathy. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. DCM is an X-linked disorder. Each of this individual''s sons has up to a 50% chance of being affected and each of her daughters has up to a 50% chance of being a carrier.'),
            (51, 8, 'TWO_CIS', 'Two variants detected (cis)', 'CARRIER for Duchenne/Becker Muscular Dystrophy', 'Positive for the ${results[0].type} variant ${results[0].variantName} and ${results[1].type} variant ${results[1].variantName} in cis (on the same chromosome) in the DMD gene. Female carriers are at an increased chance to develop cardiomyopathy or muscle weakness. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. Each of this individual''s sons has a 50% chance of being affected and each of her daughters has a 50% chance of being a carrier.'),
            (52, 3, 'DEL_DUP_DMD', 'X chromosome deletion or duplication inclusive of DMD gene or other MLPA X finding including DMD', 'INCONCLUSIVE for Duchenne/Becker Muscular Dystrophy', 'The results of MLPA analysis for the DMD gene were inconclusive suggesting ${"[deletion or duplication]"} of all DMD exons and possibly additional regions on the X chromosome ${"[add regions if applicable]"}. Chromosome microarray testing and karyotype may be indicated as follow-up in this individual. This individual may be at risk to have sons with Duchenne/Becker muscular dystrophy.'),
            (53, 6, 'DEL_A37', 'One copy 3.7 deletion', 'SILENT CARRIER for Alpha-Thalassemia (aa/a-)', 'Positive for the pathogenic alpha 3.7 deletion of the HBA2 gene. Depending on the carrier status of the individual''s partner, this couple may be at increased risk to have a child with Hemoglobin H Disease. Carrier screening for this individual''s partner is suggested.'),
            (54, 6, 'DEL_A42', 'One copy 4.2 deletion', 'SILENT CARRIER for Alpha-Thalassemia (aa/a-)', 'Positive for the pathogenic alpha 4.2 deletion of the HBA2 gene. Depending on the carrier status of the individual''s partner, this couple may be at increased risk to have a child with Hemoglobin H Disease. Carrier screening for this individual''s partner is suggested.'),
            (55, 6, 'DEL_OTHER', 'One gene deleted (rare deletion other than 3.7 or 4.2)', 'SILENT CARRIER for Alpha-Thalassemia (aa/a-)', 'Positive for the pathogenic ${results[0].variantName} deletion of the ${gene} gene. Depending on the carrier status of the individual''s partner, this couple may be at increased risk to have a child with Hemoglobin H Disease. Carrier screening for this individual''s partner is suggested.'),
            (56, 6, 'TWO_CIS', 'Two genes deleted (cis)', 'CARRIER for Alpha-Thalassemia (aa/--)', 'Positive for the pathogenic ${results[0].variantName!"[name of deletion]"} deletion of the ${gene!"[HBA1/HBA2 genes]"}. Carriers for Alpha-Thalassemia can sometimes have mild anemia. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. Depending on the carrier status of the individual''s partner, this couple may be at increased risk to have a child with either Alpha-Thalassemia Major or Hemoglobin H disease. Carrier screening for this individual''s partner is suggested.'),
            (57, 6, 'TWO_TRANS', 'Two genes deleted (trans)', 'CARRIER for Alpha-Thalassemia (a-/a-)', 'Positive for the pathogenic ${"[name of deletion(s)]"} of the ${gene!"[HBA1, HBA2, or HBA1/HBA2 genes]"}. Carriers for Alpha-Thalassemia can sometimes have mild anemia. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. Depending on the carrier status of the individual''s partner, this couple may be at increased risk to have a child with Hemoglobin H Disease. Carrier screening for this individual''s partner is suggested.'),
            (58, 6, 'TWO_UNKNOWN', 'Two genes deleted (cis or trans  unknown)', 'CARRIER for Alpha-Thalassemia', 'Positive for the pathogenic ${"[name of deletion(s)]"} of the ${gene!"[HBA1/HBA2 genes]"}. Carriers for Alpha-Thalassemia can sometimes have mild anemia. Depending on the carrier status of the individual''s partner, this couple may be at increased risk to have a child with either Alpha-Thalassemia Major or Hemoglobin H disease. Carrier screening for this individual''s partner is suggested.'),
            (59, 6, 'THREE_DEL', 'Three deletions detected', 'POSITIVE for multiple variants in the gene associated with Alpha-Thalassemia (a-/--). This genotype is associated with Hemoglobin H Disease.', 'Positive for the pathogenic ${"[name of deletion]"} and ${"[name of deletion]"} of the ${gene!"[HBA1/HBA2 genes]"}. Individuals with Hemoglobin H Disease can have mild to severe anemia. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. Depending on the carrier status of the individual''s partner, this couple may be at increased risk to have a child with either Alpha-Thalassemia Major or Hemoglobin H disease. Carrier screening for this individual''s partner is suggested.'),
            (60, 6, 'ONE_HBCS', 'One constant spring (HbCS) variant detected', 'SILENT CARRIER for Alpha-Thalassemia', 'Positive for the pathogenic Hb Constant Spring variant c.427T>C (p.Ter143Gln) in the HBA2 gene. Depending on the carrier status of the individual''s partner, this couple may be at increased risk to have a child with Hemoglobin H-Constant Spring Disease or Homozygous Constant Spring Disease. Carrier screening for this individual''s partner is suggested.'),
            (61, 6, 'ONE_HBCS_HBA2_DEL', 'One constant spring variant and HBA2 deletion detected', 'POSITIVE for two variants in the gene associated with Alpha-Thalassemia', 'Positive for the pathogenic Hb Constant Spring variant c.427T>C (p.Ter143Gln) and ${results[0].variantName} deletion of the HBA2 gene. Depending on the carrier status of the individual''s partner, this couple may be at increased risk to have a child with a form of Alpha-Thalassemia. Carrier screening for this individual''s partner is suggested.'),
            (62, 6, 'ONE_HBCS_HBA1_DEL', 'One constant spring variant and HBA1 deletion detected', 'POSITIVE for two pathogenic variants in the gene associated with Alpha-Thalassemia', 'Positive for the pathogenic Hb Constant Spring variant c.427T>C (p.Ter143Gln) and ${results[0].variantName} deletion of the HBA1 gene. It is unknown if these variants are on the same (in cis) or opposite (in trans) chromosomes. Depending on the carrier status of the individual''s partner, this couple may be at increased risk to have a child with a form of Alpha-Thalassemia. Carrier screening for this individual''s partner is suggested.'),
            (63, 6, 'TWO_HBCS', 'Two constant spring variants detected', 'POSITIVE for Homozygous Constant Spring', 'Positive for the pathogenic Hb Constant Spring variant c.427T>C (p.Ter143Gln) in both copies of the HBA2 gene. Carriers of two Constant Spring variants may have mild to severe chronic anemia. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. Depending on the carrier status of the individual''s partner, this couple may be at increased risk to have a child with Hemoglobin H-Constant Spring Disease or Homozygous Constant Spring Disease. Carrier screening for this individual''s partner is suggested.'),
            (64, 6, 'ONE_HBCS_TWO_DEL', 'One constant spring variant and two genes deleted', 'POSITIVE for multiple variants in the gene associated with Alpha-Thalassemia. This genotype is associated with Hemoglobin H-Constant Spring Disease.', 'Positive for the pathogenic Hb Constant Spring variant c.427T>C (p.Ter143Gln) and ${results[0].variantName!"[name of deletions]"} of the ${gene!"[HBA1/HBA2 genes]"}. Individuals with Hemoglobin H-Constant Spring Disease can have mild to severe anemia. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. Depending on the carrier status of the individual''s partner, this couple may be at increased risk to have a child with a form of Alpha-Thalassemia. Carrier screening for this individual''s partner is suggested.'),
            (65, 6, 'PATHOGENIC_VARIANT_BETA_HEMO', 'Pathogenic variant detected for beta-hemoglobinopathy or thalassemia', 'CARRIER for Beta-Hemoglobinopathy or Beta-Thalassemia', 'Positive for the pathogenic variant ${results[0].variantName} in the HBB gene. Carriers of Beta-Hemoglobinopathy/Beta-Thalassemia can have mild to moderate anemia. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. If this individual''s partner is a carrier for Beta-Hemoglobinopathy or Beta-Thalassemia, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (66, 6, 'HBB_c.20A>T', 'One variant detected for HbS', 'CARRIER for Sickle Cell Disease', 'Positive for the pathogenic variant ${results[0].variantName} in the HBB gene. Carriers of Sickle Cell Disease may be at risk for symptoms during physical exertion, high altitudes or when dehydrated. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. If this individual''s partner is a carrier for a Beta-Hemoglobinopathy or Beta-Thalassemia, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (67, 6, 'HBB_c.19G>A', 'One variant detected for Hb C', 'CARRIER for Hemoglobin C', 'Positive for the pathogenic variant ${results[0].variantName} in the HBB gene. If this individual''s partner is a carrier for a Beta-Hemoglobinopathy or Beta-Thalassemia, their chance to have a child with a condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (68, 6, 'HBB_c.79G>A', 'One variant detected for Hb E', 'CARRIER for Hemoglobin E', 'Positive for the pathogenic variant ${results[0].variantName} in the HBB gene. Some carriers have very mild anemia that does not typically need treatment. If this individual''s partner is a carrier for a Beta-Hemoglobinopathy or Beta-Thalassemia, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (69, 7, 'LIKELY_PATHOGENIC_BETA_HEMO', 'Likely pathogenic variant detected for beta-hemoglobinopathy or thalassemia', 'CARRIER for Beta-Hemoglobinopathy or Beta-Thalassemia', 'Positive for the likely pathogenic variant ${results[0].variantName} in the HBB gene. Carriers of Beta-Hemoglobinopathy/Beta-Thalassemia can have mild to moderate anemia. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. If this individual''s partner is a carrier for a Beta-Hemoglobinopathy or Beta-Thalassemia, their chance to have a child with this condition may be as high as 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (70, 8, 'TWO_UNKNOWN_BETA_HEMO', 'Two variants detected (cis or trans unknown) beta-hemoglobinopathy or thalassemia', 'POSITIVE for two variants in the gene associated with Beta-Hemoglobinopathy or Thalassemia', 'Positive for the ${results[0].type} variant ${results[0].variantName} and ${results[1].type} variant ${results[1].variantName} in the HBB gene. This individual may be affected with Beta-Hemoglobinopathy or Beta-Thalassemia. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. This analysis cannot determine if the HBB variants are on the same (in cis) or opposite (in trans) chromosomes in this individual. Testing of parents or other close family members may assist in determining the phase of these variants. If this individual''s partner is a carrier for Beta-Hemoglobinopathy or Beta-Thalassemia, their chance to have a child with this condition may be as high as 1 in 2 (50%). Carrier screening for this individual''s partner is suggested.'),
            (71, 8, 'TWO_CIS_BETA_HEMO', 'Two variants detected (cis) beta-hemoglobinopathy or thalassemia', 'CARRIER for Beta-Hemoglobinopathy or Thalassemia', 'Positive for the ${results[0].type} variant ${results[0].variantName} and ${results[1].type} variant ${results[1].variantName} in cis (on the same chromosome) in the HBB gene. Carriers of Beta-Hemoglobinopathy/Beta-Thalassemia can have mild to moderate anemia. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. If this individual''s partner is a carrier for Beta-Hemoglobinopathy or Beta-Thalassemia, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (72, 8, 'TWO_TRANS_BETA_HEMO', 'Two variants detected (trans) beta-hemoglobinopathy or thalassemia', 'POSITIVE for two variants in the gene associated with Beta-Hemoglobinopathy or Thalassemia', 'Positive for the ${results[0].type} variant ${results[0].variantName} and ${results[1].type} variant ${results[1].variantName} in the HBB gene. This individual is predicted to be affected with Beta-Hemoglobinopathy or Beta-Thalassemia. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. If this individual''s partner is a carrier for Beta-Hemoglobinopathy or Beta-Thalassemia, their chance to have a child with this condition may be as high as 1 in 2 (50%). Carrier screening for this individual''s partner is suggested.'),
            (73, 6, 'PATHOGENIC_BETA_THAL', 'Pathogenic variant detected for beta-thal', 'CARRIER for Beta-Thalassemia', 'Positive for the pathogenic variant ${results[0].variantName} in the HBB gene. Carriers for Beta-Thalassemia can have mild to moderate anemia. If this individual''s partner is a carrier for Beta-Thalassemia or Beta-Hemoglobinopathy, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (74, 7, 'LIKELY_PATHOGENIC_BETA_THAL', 'Likely pathogenic variant detected for beta-thalassemia', 'CARRIER for Beta-Thalassemia', 'Positive for the likely pathogenic variant ${results[0].variantName} in the HBB gene. Carriers for Beta-Thalassemia can have mild to moderate anemia. If this individual''s partner is a carrier for Beta-Thalassemia or Beta-Hemoglobinopathy, their chance to have a child with this condition may be as high as 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (75, 8, 'TWO_UNKNOWN_BETA_THAL', 'Two variants detected (cis or trans unknown) beta-thalassemia', 'POSITIVE for two variants in the gene associated with Beta-Thalassemia', 'Positive for the ${results[0].type} variant ${results[0].variantName} and ${results[1].type} variant ${results[1].variantName} in the HBB gene. This individual may be affected with Beta-Thalassemia. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. This analysis cannot determine if the HBB variants are on the same (in cis) or opposite (in trans) chromosomes in this individual. Testing of parents or other close family members may assist in determining the phase of these variants. If this individual''s partner is a carrier for Beta-Hemoglobinopathy or Thalassemia, their chance to have a child with this condition may be as high as 1 in 2 (50%). Carrier screening for this individual''s partner is suggested.'),
            (76, 8, 'TWO_CIS_BETA_THAL', 'Two variants detected (cis) beta-thalassemia', 'CARRIER for Beta-Thalassemia', 'Positive for the ${results[0].type} variant ${results[0].variantName} and ${results[1].type} variant ${results[1].variantName} in cis (on the same chromosome) in the HBB gene. If this individual''s partner is a carrier for Beta-Hemoglobinopathy or Thalassemia, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (77, 8, 'TWO_TRANS_BETA_THAL', 'Two variants detected (trans) beta-thalassemia', 'POSITIVE for two variants in the gene associated with Beta-Thalassemia', 'Positive for the ${results[0].type} variant ${results[0].variantName} and ${results[1].type} variant ${results[1].variantName} in the HBB gene. This individual is predicted to be affected with Beta-Thalassemia. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. If this individual''s partner is a carrier for Beta-Hemoglobinopathy or Thalassemia, their chance to have a child with this condition may be as high as 1 in 2 (50%). Carrier screening for this individual''s partner is suggested.'),
            (78, 39, 'SMN1_ZERO_PRESENT', '0 copies of the SMN1 gene; g.27134T>G present', 'POSITIVE Spinal Muscular Atrophy (SMA) Results', 'ZERO copies of the SMN1 gene detected. Positive for the g.27134T>G variant; this finding does not change or modify results in patients with zero SMN1 copies. If the patient''s partner is a carrier for Spinal Muscular Atrophy, their chance to have a child with this condition is 1 in 2 (50%). This patient''s result is consistent with a molecular diagnosis of Spinal Muscular Atrophy. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered, as this patient may be affected with Spinal Muscular Atrophy. Carrier screening for the patient''s partner is suggested.'),
            (79, 40, 'SMN1_ZERO_ABSENT', '0 copies of the SMN1 gene; g.27134T>G absent', 'POSITIVE Spinal Muscular Atrophy (SMA) Results', 'ZERO copies of the SMN1 gene detected. Negative for the g.27134T>G variant; this finding does not change or modify results in patients with zero SMN1 copies. If the patient''s partner is a carrier for Spinal Muscular Atrophy, their chance to have a child with this condition is 1 in 2 (50%). This patient''s result is consistent with a molecular diagnosis of Spinal Muscular Atrophy. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered, as this patient may be affected with Spinal Muscular Atrophy. Carrier screening for the patient''s partner is suggested.'),
            (80, 41, 'SMN1_ONE_PRESENT', '1 copy of the SMN1 gene; g.27134T>G present', 'CARRIER for Spinal Muscular Atrophy', 'Positive for one copy of the SMN1 gene. Positive for the g.27134T>G variant; this finding does not change or modify this individual''s carrier status. If this individual''s partner is a carrier for Spinal Muscular Atrophy, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (81, 42, 'SMN1_ONE_ABSENT', '1 copy of the SMN1 gene; g.27134T>G absent', 'CARRIER for Spinal Muscular Atrophy', 'Positive for one copy of the SMN1 gene. Negative for the g.27134T>G variant; this finding does not change or modify this individual''s carrier status. If this individual''s partner is a carrier for Spinal Muscular Atrophy, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (82, 43, 'SMN1_TWO_PRESENT_JA', '2 copies of the SMN1 gene; g.27134T>G present and Jewish or Asian ethnicity reported', 'INCREASED CARRIER RISK for Spinal Muscular Atrophy', 'Two copies of the SMN1 gene detected. Positive for the g.27134T>G variant. Based on this individual''s reported ethnicity, the individual is likely to be a silent (2+0) carrier for SMA. If this individual''s partner is a carrier for Spinal Muscular Atrophy, their chance to have a child with this condition may be as high as 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (83, 44, 'SMN1_TWO_PRESENT_C', '2 copies of the SMN1 gene; g.27134T>G present and Caucasian ethnicity reported', 'INCREASED CARRIER RISK for Spinal Muscular Atrophy', 'Two copies of the SMN1 gene detected. Positive for the g.27134T>G variant. Based on this individual''s reported ethnicity, the individual has a 1 in 29 risk to be a silent (2+0) carrier for SMA. If this individual''s partner is a carrier for Spinal Muscular Atrophy, they may be at increased risk to have a child with this condition. Carrier screening for this individual''s partner is suggested.'),
            (84, 45, 'SMN1_TWO_PRESENT_AA', '2 copies of the SMN1 gene; g.27134T>G present and African-American ethnicity reported', 'INCREASED CARRIER RISK for Spinal Muscular Atrophy', 'Two copies of the SMN1 gene detected. Positive for the g.27134T>G variant. Based on this individual''s reported ethnicity, the individual has a 1 in 34 risk to be a silent (2+0) carrier for SMA. If this individual''s partner is a carrier for Spinal Muscular Atrophy, they may be at increased risk to have a child with this condition. Carrier screening for this individual''s partner is suggested.'),
            (85, 46, 'SMN1_TWO_PRESENT_H', '2 copies of the SMN1 gene; g.27134T>G present and Hispanic ethnicity reported', 'INCREASED CARRIER RISK for Spinal Muscular Atrophy', 'Two copies of the SMN1 gene detected. Positive for the g.27134T>G variant. Based on this individual''s reported ethnicity, the individual has a 1 in 140 risk to be a silent (2+0) carrier for SMA. If this individual''s partner is a carrier for Spinal Muscular Atrophy, they may be at increased risk to have a child with this condition. Carrier screening for this individual''s partner is suggested.'),
            (86, 47, 'SMN1_TWO_PRESENT', '2 copies of the SMN1 gene; g.27134T>G present and no ethnicity reported', 'INCREASED CARRIER RISK for Spinal Muscular Atrophy', 'Two copies of the SMN1 gene detected. Positive for the g.27134T>G variant. The individual has an increased risk to be a silent (2+0) carrier for SMA. If this individual''s partner is a carrier for Spinal Muscular Atrophy, they may be at increased risk to have a child with this condition. Carrier screening for this individual''s partner is suggested.'),
            (87, 48, 'SMN1_TWO_ABSENT', '2 copies of the SMN1 gene; g.27134T>G absent', 'NEGATIVE Spinal Muscular Atrophy (SMA) Results', 'SMN1: Two copies; g.27134T>G: absent; the absence of the g.27134T>G variant decreases the chance to be a silent (2+0) carrier.'),
            (88, 49, 'SMN1_THREE_PRESENT', '3 or more copies of the SMN1 gene; g.27134T>G present', 'NEGATIVE Spinal Muscular Atrophy (SMA) Results', 'SMN1: ${"[number of SMN1 copies]"} copies; g.27134T>G: present; the g.27134T>G variant does not modify carrier risk in individuals who carry 3 or more copies of SMN1.'),
            (89, 50, 'SMN1_THREE_ABSENT', '3 or more copies of the SMN1 gene; g.27134T>G absent', 'NEGATIVE Spinal Muscular Atrophy (SMA) Results', 'SMN1: ${"[number of SMN1 copies]"} copies; g.27134T>G: absent; the g.27134T>G variant does not modify carrier risk in individuals who carry 3 or more copies of SMN1.'),
            (90, 3, '_ENZYME_DETAILS', '_enzyme_details', '', 'Hexosaminidase Activity. Plasma: ${results[0].plasma.hexActivity} nmol/hr/ml; WBC: ${results[0].wbc.hexActivity} nmol/hr/mg; Hex A %. Plasma ${results[0].plasma.hexAPercentage}; WBC ${results[0].wbc.hexAPercentage}.'),
            (91, 6, '_PATHOGENIC', '_tsd_pathogenic', '', 'Positive for the pathogenic variant ${results[0].hgvsVariantName} in the HEXA gene.'),
            (92, 7, '_LIKELY_PATHOGENIC', '_tsd_likely_pathogenic', '', 'Positive for the likely pathogenic variant ${results[0].hgvsVariantName} in the HEXA gene.'),
            (93, 6, '_ONE_PSEUDODEFICIENT', '_tsd_pseudodeficient', '', 'The pseudodeficiency variant ${results[0].hgvsVariantName} was detected in the HEXA gene.'),
            (94, 8, '_TWO_PSEUDODEFICIENT', '_tsd_two_pseudodeficient', '', 'Two pseudodeficiency variants ${result[0].hgvsVariantName} and ${result[1].hgvsVariantName} were detected in the HEXA gene.'),
            (95, 6, '_PATHOGENIC_PSEUDODEFICIENT', '_tsd_pathogenic_pseudodeficient', '', 'Positive for the pathogenic variant ${results[0].hgvsVariantName} and the pseudodeficiency variant ${results[1].hgvsVariantName} in the HEXA gene.'),
            (96, 8, '_TWO_CIS', '_tsd_two_cis', '', 'Positive for the ${result[0].type} variant ${result[0].hgvsVariantName} and ${result[1].type} variant ${result[0].hgvsVariantName} in cis (on the same chromosome) in the HEXA gene.'),
            (97, 8, '_TWO', '_tsd_two', '', 'Positive for the ${result[0].type} variant ${result[0].hgvsVariantName} and ${result[1].type} variant ${result[0].hgvsVariantName} in the HEXA gene.'),
            (98, 32, '_ENZYME_POSITIVE', '_tse_positive_enzyme', '', 'Positive enzyme analysis. ${_enzyme_details}'),
            (99, 33, '_ENZYME_INDETERMINATE', '_tse_indeterminate_enzyme', '', 'Indeterminate enzyme analysis. ${_enzyme_details}'),
            (100, 2, '_ENZYME_NEGATIVE', '_tse_negative_enzyme', '', 'Negative enzyme analysis. ${_enzyme_details}'),
            (101, 2, 'ENZYME_NEGATIVE', 'No DNA; Enzyme analysis within normal limits', 'NEGATIVE Tay-Sachs Disease Results', 'Normal ${_enzyme_details}'),
            (102, 32, 'ENZYME_POSITIVE', 'No DNA; positive enzyme', 'CARRIER for Tay-Sachs Disease', '${_tse_positive_enzyme} If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested. A combination of both DNA and enzyme screening provides the highest detection rate for Tay-Sachs Disease.'),
            (103, 33, 'ENZYME_INDETERMINATE', 'No DNA; indeterminate enzyme', 'INDETERMINATE ENZYME ANALYSIS for Tay-Sachs Disease', '${_tse_indeterminate_enzyme} Redraw recommended.'),
            (104, 34, 'ENZYME_INDETERMINATE_SANDHOFF', 'No DNA; indeterminate enzyme (possible Sandhoff carrier)', 'INDETERMINATE ENZYME ANALYSIS for Tay-Sachs Disease', '${_tse_indeterminate_enzyme} The Hex A% activity is high in this specimen suggesting a possible carrier status for Sandhoff disease. It is recommended that the individual have enzyme analysis for Sandhoff disease through another laboratory.'),
            (105, 6, 'PATHOGENIC', 'Pathogenic variant detected', 'CARRIER for Tay-Sachs Disease', '${_tsd_pathogenic} If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested. A combination of both DNA and enzyme screening provides the highest detection rate for Tay-Sachs Disease.'),
            (106, 6, 'PSEUDODEFICIENT', 'Pseudodeficiency variant detected', 'Pseudodeficiency VARIANT DETECTED for Tay-Sachs Disease', '${_tsd_pseudodeficient} This pseudodeficiency allele is known to cause false positive results on enzyme-based Tay-Sachs Disease carrier screening. This benign variant does not increase the risk for Tay-Sachs Disease in this individual''s children.'),
            (107, 6, 'PATHOGENIC_PSEUDODEFICIENT', 'One pathogenic variant and one pseudodeficiency variant detected', 'CARRIER for Tay-Sachs Disease', '${_tsd_pathogenic_pseudodeficient} If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested. A combination of both DNA and enzyme screening provides the highest detection rate for Tay-Sachs Disease.'),
            (108, 7, 'LIKELY_PATHOGENIC', 'Likely pathogenic variant detected', 'CARRIER for Tay-Sachs Disease', '${_tds_likely_pathogenic} If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition may be as high as 1 in 4 (25%). Carrier screening for this individual''s partner is suggested. A combination of both DNA and enzyme screening provides the highest detection rate for Tay-Sachs Disease.'),
            (109, 8, 'TWO_UNKNOWN', 'Two variants detected (cis or trans unknown)', 'POSITIVE for two variants in the gene associated with Tay-Sachs Disease', '${_tsd_two} This individual may be affected with Tay-Sachs Disease. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. This analysis cannot determine if the HEXA variants are on the same (in cis) or opposite (in trans) chromosomes in this individual. Testing of parents or other close family members may assist in determining the phase of these variants. If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition may be as high as 1 in 2 (50%). Carrier screening for this individual''s partner is suggested. A combination of both DNA and enzyme screening provides the highest detection rate for Tay-Sachs Disease.'),
            (110, 8, 'TWO_CIS', 'Two variants detected (cis)', 'CARRIER for Tay-Sachs Disease', '${_tsd_two_cis} If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested. A combination of both DNA and enzyme screening provides the highest detection rate for Tay-Sachs Disease.'),
            (111, 8, 'TWO_TRANS', 'Two variants detected (trans)', 'POSITIVE for two variants in the gene associated with Tay-Sachs Disease', '${_tsd_two} This individual is predicted to be affected with Tay-Sachs Disease. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition may be as high as 1 in 2 (50%). Carrier screening for this individual''s partner is suggested. A combination of both DNA and enzyme screening provides the highest detection rate for Tay-Sachs Disease.'),
            (112, 2, 'NEGATIVE__NEGATIVE', 'No variants detected; negative enzyme', 'NEGATIVE Tay-Sachs Disease Results', 'No pathogenic variants detected. Normal ${_enzyme_details}'),
            (113, 32, 'NEGATIVE__POSTIVE', 'No variants detected; positive enzyme', 'CARRIER for Tay-Sachs Disease', 'No pathogenic variants detected. ${_tse_positive_enzyme} If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested. A combination of both DNA and enzyme screening provides the highest detection rate for Tay-Sachs Disease.'),
            (114, 33, 'NEGATIVE__INDETERMINATE', 'No variants detected; indeterminate enzyme', 'INDETERMINATE ENZYME ANALYSIS for Tay-Sachs Disease', 'No pathogenic variants detected. ${_tse_indeterminate_enzyme} Redraw recommended.'),
            (115, 34, 'NEGATIVE__INDETERMINATE_SANDHOFF', 'No variants detected; indeterminate enzyme (possible Sandhoff carrier)', 'NEGATIVE ENZYME ANALYSIS for Tay-Sachs Disease', 'NEGATIVE ENZYME ANALYSIS for Tay-Sachs Disease. No pathogenic variants were detected in the HEXA gene for Tay-Sachs. ${_enz_details}'),
            (116, 7, 'LIKELY_PATHOGENIC__POSITIVE', 'Likely pathogenic variant detected; positive enzyme analysis', 'CARRIER for Tay-Sachs Disease', '${_tsd_likely_pathogenic} ${_tse_positive_enzyme} If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested. A combination of both DNA and enzyme screening provides the highest detection rate for Tay-Sachs Disease.'),
            (117, 7, 'LIKELY_PATHOGENIC__INDETERMINATE', 'Likely pathogenic variant detected; indeterminate enzyme analysis', 'CARRIER for Tay-Sachs Disease', '${_tsd_likely_pathogenic} ${_tse_indeterminate_enzyme} If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested. A combination of both DNA and enzyme screening provides the highest detection rate for Tay-Sachs Disease.'),
            (118, 6, 'PATHOGENIC__POSITIVE', 'One pathogenic variant detected; positive enzyme analysis', 'CARRIER for Tay-Sachs Disease', '${_tsd_pathogenic} ${_tse_positive_enzyme} If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested. A combination of both DNA and enzyme screening provides the highest detection rate for Tay-Sachs Disease.'),
            (119, 6, 'PATHOGENIC__INDETERMINATE', 'One pathogenic variant detected; indeterminate enzyme analysis', 'CARRIER for Tay-Sachs Disease', '${_tsd_pathogenic} ${_tse_indeterminate_enzyme} If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested. A combination of both DNA and enzyme screening provides the highest detection rate for Tay-Sachs Disease.'),
            (120, 6, 'PSEUDODEFICIENT__POSITIVE', 'One pseudodeficiency variant detected; positive enzyme', 'Pseudodeficiency VARIANT DETECTED for Tay-Sachs Disease', '${_tsd_pseudodeficient} ${_tse_positive_enzyme} This pseudodeficiency allele is known to cause false positive results on enzyme-based Tay-Sachs Disease carrier screening. This benign variant does not increase the risk for Tay-Sachs Disease in this individual''s children.'),
            (121, 6, 'PSEUDODEFICIENT__NEGATIVE', 'One pseudodeficiency variant detected; negative enzyme', 'Pseudodeficiency VARIANT DETECTED for Tay-Sachs Disease', '${_tsd_pseudodeficient} ${_tse_negative_enzyme} This pseudodeficiency allele is known to cause false positive results on enzyme-based Tay-Sachs Disease carrier screening. This benign variant does not increase the risk for Tay-Sachs Disease in this individual''s children.'),
            (122, 6, 'PSEUDODEFICIENT__INDETERMINATE', 'One pseudodeficiency variant detected; indeterminate enzyme', 'Pseudodeficiency VARIANT DETECTED for Tay-Sachs Disease', '${_tsd_pseudodeficient} ${_tse_indeterminate_enzyme} This pseudodeficiency allele is known to cause false positive results on enzyme-based Tay-Sachs Disease carrier screening. This benign variant does not increase the risk for Tay-Sachs Disease in this individual''s children.'),
            (123, 6, 'PATHOGENIC_PSEUDODEFICIENT__POSTIVE', 'One pathogenic variant and one pseudodeficiency variant detected; positive enzyme', 'CARRIER for Tay-Sachs Disease', '${_tsd_pathogenic_pseudodeficient} ${_tse_positive_enzyme} If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested. A combination of both DNA and enzyme screening provides the highest detection rate for Tay-Sachs Disease.'),
            (124, 6, 'PATHOGENIC_PSEUDODEFICIENT__NEGATIVE', 'One pathogenic variant and one pseudodeficiency variant detected; negative enzyme', 'CARRIER for Tay-Sachs Disease', '${_tsd_pathogenic_pseudodeficient} ${_tse_negative_enzyme} If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested. A combination of both DNA and enzyme screening provides the highest detection rate for Tay-Sachs Disease.'),
            (125, 6, 'PATHOGENIC_PSEUDODEFICIENT__INDETERMINATE', 'One pathogenic variant and one pseudodeficiency variant detected; indeterminate enzyme', 'CARRIER for Tay-Sachs Disease', '${_tsd_pathogenic_pseudodeficient} ${_tse_indeterminate_enzyme} If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested. A combination of both DNA and enzyme screening provides the highest detection rate for Tay-Sachs Disease.'),
            (126, 8, 'TWO_PSEUDODEFICIENT__POSITIVE', 'Two pseudodeficiency variants detected; positive enzyme', 'Two Pseudodeficiency VARIANTS DETECTED for Tay-Sachs Disease', '${_tsd_two_pseudodeficient} ${_tse_positive_enzyme} These pseudodeficiency alleles are known to cause false positive results on enzyme-based Tay-Sachs Disease carrier screening and do not increase the risk for Tay-Sachs Disease in this individual''s children.'),
            (127, 8, 'TWO_PSEUDODEFICIENT__NEGATIVE', 'Two pseudodeficiency variants detected; negative enzyme', 'Two Pseudodeficiency VARIANTS DETECTED for Tay-Sachs Disease', '${_tsd_two_pseudodeficient} ${_tse_negative_enzyme} These pseudodeficiency alleles do not increase the risk for Tay-Sachs Disease in this individual''s children.'),
            (128, 8, 'TWO_PSEUDODEFICIENT__INDETERMINATE', 'Two pseudodeficiency variants detected; indeterminate enzyme', 'Two Pseudodeficiency VARIANTS DETECTED for Tay-Sachs Disease', '${_tsd_two_pseudodeficient} ${_tse_indeterminate_enzyme} These pseudodeficiency alleles are known to cause false positive results on enzyme-based Tay-Sachs Disease carrier screening and do not increase the risk for Tay-Sachs Disease in this individual''s children.'),
            (129, 8, 'TWO_UNKNOWN__POSITIVE', 'Two variants detected (cis or trans unknown); positive enzyme', 'POSITIVE for two variants in the gene associated with Tay-Sachs Disease', '${_tsd_two} ${_tse_positive_enzyme} This individual may be affected with Tay-Sachs Disease. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. This analysis cannot determine if the HEXA variants are on the same (in cis) or opposite (in trans) chromosomes in this individual. Testing of parents or other close family members may assist in determining the phase of these variants. If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition may be as high as 1 in 2 (50%). Carrier screening for this individual''s partner is suggested. A combination of both DNA and enzyme screening provides the highest detection rate for Tay-Sachs Disease.'),
            (130, 8, 'TWO_CIS__POSITIVE', 'Two variants detected (cis); positive enzyme', 'CARRIER for Tay-Sachs Disease', '${_tsd_two_cis} ${_tse_positive_enzyme} If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested. A combination of both DNA and enzyme screening provides the highest detection rate for Tay-Sachs Disease.'),
            (131, 8, 'TWO_TRANS__POSITIVE', 'Two variants detected (trans); positive enzyme', 'POSITIVE for two variants in the gene associated with Tay-Sachs Disease', '${_tsd_two} ${_tse_positive_enzyme} This individual is predicted to be affected with Tay-Sachs Disease. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition may be as high as 1 in 2 (50%). Carrier screening for this individual''s partner is suggested. A combination of both DNA and enzyme screening provides the highest detection rate for Tay-Sachs Disease.'),
            (132, 8, 'TWO_UNKNOWN__INDETERMINATE', 'Two variants detected (cis or trans unknown); indeterminate enzyme', 'POSITIVE for two variants in the gene associated with Tay-Sachs Disease', '${_tsd_two} ${_tse_indeterminate_enzyme} This individual may be affected with Tay-Sachs Disease. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. This analysis cannot determine if the HEXA variants are on the same (in cis) or opposite (in trans) chromosomes in this individual. Testing of parents or other close family members may assist in determining the phase of these variants. If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition may be as high as 1 in 2 (50%). Carrier screening for this individual''s partner is suggested. A combination of both DNA and enzyme screening provides the highest detection rate for Tay-Sachs Disease.'),
            (133, 8, 'TWO_CIS__INDETERMINATE', 'Two variants detected (cis); indeterminate enzyme', 'CARRIER for Tay-Sachs Disease', '${_tsd_two_cis} ${_tse_indeterminate_enzyme} If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested. A combination of both DNA and enzyme screening provides the highest detection rate for Tay-Sachs Disease.'),
            (134, 8, 'TWO_TRANS__INDETERMINATE', 'Two variants detected (trans); indeterminate enzyme', 'POSITIVE for two variants in the gene associated with Tay-Sachs Disease', '${_tsd_two} ${_tse_indeterminate_enzyme} This individual is predicted to be affected with Tay-Sachs Disease. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition may be as high as 1 in 2 (50%). Carrier screening for this individual''s partner is suggested. A combination of both DNA and enzyme screening provides the highest detection rate for Tay-Sachs Disease.'),
            (135, 8, 'TWO_UNKNOWN__NEGATIVE', 'Two variants detected (cis or trans unknown); negative enzyme', 'POSITIVE for two variants in the gene associated with Tay-Sachs Disease', '${_tsd_two} ${_tse_negative_enzyme} This individual may be affected with Tay-Sachs Disease. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. This analysis cannot determine if the HEXA variants are on the same (in cis) or opposite (in trans) chromosomes in this individual. Testing of parents or other close family members may assist in determining the phase of these variants. If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition may be as high as 1 in 2 (50%).'),
            (136, 8, 'TWO_CIS__NEGATIVE', 'Two variants detected (cis); negative enzyme', 'CARRIER for Tay-Sachs Disease', '${_tsd_two_cis} ${_tse_negative_enzyme} If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested. A combination of both DNA and enzyme screening provides the highest detection rate for Tay-Sachs Disease.'),
            (137, 8, 'TWO_TRANS__NEGATIVE', 'Two variants detected (trans); negative enzyme', 'POSITIVE for two variants in the gene associated with Tay-Sachs Disease', '${_tsd_two} ${_tse_negative_enzyme} This individual is predicted to be affected with Tay-Sachs Disease. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. If this individual''s partner is a carrier for Tay-Sachs Disease, their chance to have a child with this condition may be as high as 1 in 2 (50%). Carrier screening for this individual''s partner is suggested. A combination of both DNA and enzyme screening provides the highest detection rate for Tay-Sachs Disease.'),
            (138, 6, 'GBA_c.1226A>G', 'c.1226A>G (p.N409S) (N370S)', 'CARRIER for Gaucher Disease', 'Positive for the pathogenic variant c.1226A>G (p.N409S) (N370S) in the GBA gene. Please note, individuals with at least one copy of the c.1226A>G (p.N409S) (N370S) variant do not develop primary neurologic disease. When present in the homozygous form, the disease phenotype may vary from asymptomatic to severe, although usually tends to be milder than the disease resulting from other genotypes. If the patient''s partner is a carrier for Gaucher Disease, their chance to have a child with this condition is 1 in 4 (25%). Carrier screening for this individual''s partner is suggested.'),
            (139, 6, 'PATHOGENIC', 'One pathogenic point mutation', 'SILENT CARRIER for Alpha-Thalassemia', 'Positive for the pathogenic variant ${results[0].variantName} of the ${gene!"[HBA1, HBA2, or HBA1/HBA2 genes]"}. Depending on the carrier status of this individual''s partner, this couple may be at increased risk to have a child with a form of Alpha-Thalassemia. Carrier screening for this individual''s partner is suggested.'),
            (140, 6, 'LIKELY_PATHOGENIC', 'One likely pathogenic point mutation', 'SILENT CARRIER for Alpha-Thalassemia', 'Positive for the likely pathogenic variant ${results[0].variantName} of the ${gene!"[HBA1, HBA2, or HBA1/HBA2 genes]"}. Depending on the carrier status of this individual''s partner, this couple may be at increased risk to have a child with a form of Alpha-Thalassemia. Carrier screening for this individual''s partner is suggested.'),
            (141, 6, 'ONE_DEL_ONE_MUT_CIS', 'One gene deleted and one point mutation (cis)', 'Positive for two variants in the genes for Alpha-Thalassemia', 'Positive for the ${results[0].type} variant ${results[0].variantName} and the pathogenic ${results[1].variantName} of the ${gene!"[HBA1, HBA2, or HBA1/HBA2 genes]"}. Carriers for Alpha-Thalassemia can sometimes have mild anemia. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. Depending on the carrier status of the individual''s partner, this couple may be at increased risk to have a child with a form of Alpha-Thalassemia. Carrier screening for this individual''s partner is suggested.'),
            (142, 6, 'ONE_DEL_ONE_MUT_TRANS', 'One gene deleted and one point mutation (trans)', 'Positive for two variants in the genes for Alpha-Thalassemia', 'Positive for the ${results[0].type} variant ${results[0].variantName} and the pathogenic ${results[1].variantName} of the ${gene!"[HBA1, HBA2, or HBA1/HBA2 genes]"}. Carriers for Alpha-Thalassemia can sometimes have mild anemia. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. Depending on the carrier status of the individual''s partner, this couple may be at increased risk to have a child with a form of Alpha-Thalassemia. Carrier screening for this individual''s partner is suggested.'),
            (143, 6, 'ONE_DEL_ONE_MUT_UNKNOWN', 'One gene deleted and one point mutation (cis or trans unknown)', 'Positive for two variants in the genes for Alpha-Thalassemia', 'Positive for the ${results[0].type} variant ${results[0].variantName} and the pathogenic ${results[1].variantName} of the ${gene!"[HBA1, HBA2, or HBA1/HBA2 genes]"}. The laboratory is currently unable to determine whether these two variants are located on the same or opposite chromosomes. Testing of this individual''s parents or other closely related family members may assist in determining if these variants are in cis or trans. Comprehensive genetic counseling and additional medical workup as clinically indicated should be considered. Depending on the carrier status of this individual''s partner, this couple may be at increased risk to have a child with a form of Alpha-Thalassemia. Carrier screening for this individual''s partner is suggested.');

            INSERT INTO `prodlims`.`HorizonDiseaseResultTemplate_HorizonDiseaseResultTemplate`
            (`diseaseResultTemplate_id`, `subtemplates_id`, `processingOrder`)
            VALUES
            (98, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_DETAILS'), 0),
            (99, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_DETAILS'), 0),
            (100, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_DETAILS'), 0),
            (101, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_DETAILS'), 0),
            (102, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_POSITIVE'), 0),
            (103, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_INDETERMINATE'), 0),
            (104, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_INDETERMINATE'), 0),
            (105, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_PATHOGENIC'), 0),
            (106, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ONE_PSEUDODEFICIENT'), 0),
            (107, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_PATHOGENIC_PSEUDODEFICIENT'), 0),
            (108, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_LIKELY_PATHOGENIC'), 0),
            (109, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_TWO'), 0),
            (110, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_TWO_CIS'), 0),
            (111, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_TWO'), 0),
            (112, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_DETAILS'), 0),
            (113, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_POSITIVE'), 0),
            (114, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_INDETERMINATE'), 0),
            (115, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_DETAILS'), 0),

            (116, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_LIKELY_PATHOGENIC'), 0),
            (117, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_LIKELY_PATHOGENIC'), 0),
            (118, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_PATHOGENIC'), 0),
            (119, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_PATHOGENIC'), 0),
            (120, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ONE_PSEUDODEFICIENT'), 0),
            (121, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ONE_PSEUDODEFICIENT'), 0),
            (122, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ONE_PSEUDODEFICIENT'), 0),
            (123, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_PATHOGENIC_PSEUDODEFICIENT'), 0),
            (124, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_PATHOGENIC_PSEUDODEFICIENT'), 0),
            (125, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_PATHOGENIC_PSEUDODEFICIENT'), 0),
            (126, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_TWO_PSEUDODEFICIENT'), 0),
            (127, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_TWO_PSEUDODEFICIENT'), 0),
            (128, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_TWO_PSEUDODEFICIENT'), 0),
            (129, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_TWO'), 0),
            (130, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_TWO_CIS'), 0),
            (131, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_TWO'), 0),
            (132, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_TWO'), 0),
            (133, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_TWO_CIS'), 0),
            (134, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_TWO'), 0),
            (135, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_TWO'), 0),
            (136, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_TWO_CIS'), 0),
            (137, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_TWO'), 0),

            (116, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_POSITIVE'), 1),
            (117, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_INDETERMINATE'), 1),
            (118, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_POSITIVE'), 1),
            (119, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_INDETERMINATE'), 1),
            (120, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_POSITIVE'), 1),
            (121, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_NEGATIVE'), 1),
            (122, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_INDETERMINATE'), 1),
            (123, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_POSITIVE'), 1),
            (124, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_NEGATIVE'), 1),
            (125, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_INDETERMINATE'), 1),
            (126, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_POSITIVE'), 1),
            (127, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_NEGATIVE'), 1),
            (128, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_INDETERMINATE'), 1),
            (129, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_POSITIVE'), 1),
            (130, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_POSITIVE'), 1),
            (131, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_POSITIVE'), 1),
            (132, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_INDETERMINATE'), 1),
            (133, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_INDETERMINATE'), 1),
            (134, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_INDETERMINATE'), 1),
            (135, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_NEGATIVE'), 1),
            (136, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_NEGATIVE'), 1),
            (137, (SELECT `id` FROM `prodlims`.`HorizonDiseaseResultTemplate` WHERE `lookupCode` = '_ENZYME_NEGATIVE'), 1);

            SET FOREIGN_KEY_CHECKS=1;
            SET SQL_SAFE_UPDATES=1;
        </sql>
        <!-- Rollback: Tables will be dropped if Horizon rolled back. -->
        <rollback/>
    </changeSet>
    <changeSet id="ENG-6333-04" author="mdaly">
        <comment>Delete any existing disease-template associations and recreate with newer templates.</comment>
        <sql>
            SET SQL_SAFE_UPDATES=0;

            DELETE FROM `prodlims`.`HorizonDisease_HorizonDiseaseResultTemplate`;

            -- Negative, 3 var
            INSERT INTO `prodlims`.`HorizonDisease_HorizonDiseaseResultTemplate` (`diseaseResultTemplate_id`, `disease_id`) SELECT 1, `id` FROM `prodlims`.`horizondisease` WHERE `provider` = 'NATERA_LAB' AND `inheritancePattern` IN ('AUTOSOMAL_RECESSIVE', 'X_LINKED') AND `cloudId` NOT IN ('FMR1', 'SMN1', 'TSE', 'TSCOMBO');
            INSERT INTO `prodlims`.`HorizonDisease_HorizonDiseaseResultTemplate` (`diseaseResultTemplate_id`, `disease_id`) SELECT 22, `id` FROM `prodlims`.`horizondisease` WHERE `provider` = 'NATERA_LAB' AND `inheritancePattern` IN ('AUTOSOMAL_RECESSIVE', 'X_LINKED') AND `cloudId` NOT IN ('FMR1', 'SMN1', 'TSE', 'TSCOMBO');

            -- Other, TNPs
            INSERT INTO `prodlims`.`HorizonDisease_HorizonDiseaseResultTemplate` (`diseaseResultTemplate_id`, `disease_id`) SELECT 2, `id` FROM `prodlims`.`horizondisease` WHERE `provider` = 'NATERA_LAB';
            INSERT INTO `prodlims`.`HorizonDisease_HorizonDiseaseResultTemplate` (`diseaseResultTemplate_id`, `disease_id`) SELECT 3, `id` FROM `prodlims`.`horizondisease` WHERE `provider` = 'NATERA_LAB';
            INSERT INTO `prodlims`.`HorizonDisease_HorizonDiseaseResultTemplate` (`diseaseResultTemplate_id`, `disease_id`) SELECT 4, `id` FROM `prodlims`.`horizondisease` WHERE `provider` = 'NATERA_LAB';

            -- (AR) Path, Likely path, 2 variants
            INSERT INTO `prodlims`.`HorizonDisease_HorizonDiseaseResultTemplate` (`diseaseResultTemplate_id`, `disease_id`) SELECT 12, `id` FROM `prodlims`.`horizondisease` WHERE `provider` = 'NATERA_LAB' AND `inheritancePattern` = 'AUTOSOMAL_RECESSIVE' AND `cloudId` NOT IN ('ATHAL', 'SMN1', 'HEXA', 'TSE', 'TSCOMBO');
            INSERT INTO `prodlims`.`HorizonDisease_HorizonDiseaseResultTemplate` (`diseaseResultTemplate_id`, `disease_id`) SELECT 13, `id` FROM `prodlims`.`horizondisease` WHERE `provider` = 'NATERA_LAB' AND `inheritancePattern` = 'AUTOSOMAL_RECESSIVE' AND `cloudId` NOT IN ('ATHAL', 'SMN1', 'HEXA', 'TSE', 'TSCOMBO');
            INSERT INTO `prodlims`.`HorizonDisease_HorizonDiseaseResultTemplate` (`diseaseResultTemplate_id`, `disease_id`) SELECT 14, `id` FROM `prodlims`.`horizondisease` WHERE `provider` = 'NATERA_LAB' AND `inheritancePattern` = 'AUTOSOMAL_RECESSIVE' AND `cloudId` NOT IN ('ATHAL', 'SMN1', 'HEXA', 'TSE', 'TSCOMBO');
            INSERT INTO `prodlims`.`HorizonDisease_HorizonDiseaseResultTemplate` (`diseaseResultTemplate_id`, `disease_id`) SELECT 15, `id` FROM `prodlims`.`horizondisease` WHERE `provider` = 'NATERA_LAB' AND `inheritancePattern` = 'AUTOSOMAL_RECESSIVE' AND `cloudId` NOT IN ('ATHAL', 'SMN1', 'HEXA', 'TSE', 'TSCOMBO');
            INSERT INTO `prodlims`.`HorizonDisease_HorizonDiseaseResultTemplate` (`diseaseResultTemplate_id`, `disease_id`) SELECT 16, `id` FROM `prodlims`.`horizondisease` WHERE `provider` = 'NATERA_LAB' AND `inheritancePattern` = 'AUTOSOMAL_RECESSIVE' AND `cloudId` NOT IN ('ATHAL', 'SMN1', 'HEXA', 'TSE', 'TSCOMBO');

            -- (XL) Path, Likely path, 2 variants, excl DMD: it has its own templates...
            INSERT INTO `prodlims`.`HorizonDisease_HorizonDiseaseResultTemplate` (`diseaseResultTemplate_id`, `disease_id`) SELECT 17, `id` FROM `prodlims`.`horizondisease` WHERE `provider` = 'NATERA_LAB' AND `inheritancePattern` = 'X_LINKED' AND `cloudId` NOT IN ('DMD', 'FMR1');
            INSERT INTO `prodlims`.`HorizonDisease_HorizonDiseaseResultTemplate` (`diseaseResultTemplate_id`, `disease_id`) SELECT 18, `id` FROM `prodlims`.`horizondisease` WHERE `provider` = 'NATERA_LAB' AND `inheritancePattern` = 'X_LINKED' AND `cloudId` NOT IN ('DMD', 'FMR1');
            INSERT INTO `prodlims`.`HorizonDisease_HorizonDiseaseResultTemplate` (`diseaseResultTemplate_id`, `disease_id`) SELECT 20, `id` FROM `prodlims`.`horizondisease` WHERE `provider` = 'NATERA_LAB' AND `inheritancePattern` = 'X_LINKED' AND `cloudId` NOT IN ('DMD', 'FMR1');
            -- ...except for the two vars unknown and two vars trans
            INSERT INTO `prodlims`.`HorizonDisease_HorizonDiseaseResultTemplate` (`diseaseResultTemplate_id`, `disease_id`) SELECT 19, `id` FROM `prodlims`.`horizondisease` WHERE `provider` = 'NATERA_LAB' AND `inheritancePattern` = 'X_LINKED' AND `cloudId` NOT IN ('FMR1');
            INSERT INTO `prodlims`.`HorizonDisease_HorizonDiseaseResultTemplate` (`diseaseResultTemplate_id`, `disease_id`) SELECT 21, `id` FROM `prodlims`.`horizondisease` WHERE `provider` = 'NATERA_LAB' AND `inheritancePattern` = 'X_LINKED' AND `cloudId` NOT IN ('FMR1');

            INSERT INTO `prodlims`.`HorizonDisease_HorizonDiseaseResultTemplate` (`diseaseResultTemplate_id`, `disease_id`)
            VALUES
            (5, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'ACADM')),
            (6, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'ASS1')),
            (7, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'CFTR')),
            (8, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'GALT')),
            (9, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'HBB')),
            (10, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'SMPD1')),
            (11, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'SMPD1')),
            (138, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudid` = 'GBA')),
            (23, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'FMR1')),
            (24, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'FMR1')),
            (25, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'FMR1')),
            (26, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'FMR1')),
            (27, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'FMR1')),
            (28, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'FMR1')),
            (29, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'FMR1')),
            (30, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'FMR1')),
            (31, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'FMR1')),
            (32, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'FMR1')),
            (33, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'FMR1')),
            (34, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'FMR1')),
            (35, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'FMR1')),
            (36, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'FMR1')),
            (37, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'FMR1')),
            (38, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'FMR1')),
            (39, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'FMR1')),
            (40, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'CFTR')),
            (41, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'CFTR')),
            (42, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'CFTR')),
            (43, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'CFTR')),
            (44, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'CFTR')),
            (45, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'CFTR')),
            (46, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'CFTR')),
            (47, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'DMD')),
            (48, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'DMD')),
            (49, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'DMD')),
            (50, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'DMD')),
            (51, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'DMD')),
            (52, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'DMD')),
            (53, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'ATHAL')),
            (54, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'ATHAL')),
            (55, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'ATHAL')),
            (56, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'ATHAL')),
            (57, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'ATHAL')),
            (58, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'ATHAL')),
            (59, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'ATHAL')),
            (60, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'ATHAL')),
            (61, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'ATHAL')),
            (62, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'ATHAL')),
            (63, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'ATHAL')),
            (64, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'ATHAL')),
            (139, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudid` = 'ATHAL')),
            (140, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudid` = 'ATHAL')),
            (141, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudid` = 'ATHAL')),
            (142, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudid` = 'ATHAL')),
            (143, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudid` = 'ATHAL')),
            (65, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'HBB')),
            (66, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'HBB')),
            (67, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'HBB')),
            (68, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'HBB')),
            (69, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'HBB')),
            (70, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'HBB')),
            (71, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'HBB')),
            (72, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'HBB')),
            (73, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'HBB')),
            (74, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'HBB')),
            (75, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'HBB')),
            (76, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'HBB')),
            (77, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'HBB')),
            (78, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'SMN1')),
            (79, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'SMN1')),
            (80, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'SMN1')),
            (81, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'SMN1')),
            (82, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'SMN1')),
            (83, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'SMN1')),
            (84, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'SMN1')),
            (85, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'SMN1')),
            (86, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'SMN1')),
            (87, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'SMN1')),
            (88, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'SMN1')),
            (89, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'SMN1')),
            (101, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSE')),
            (102, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSE')),
            (103, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSE')),
            (104, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSE')),
            (105, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'HEXA')),
            (106, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'HEXA')),
            (107, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'HEXA')),
            (108, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'HEXA')),
            (109, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'HEXA')),
            (110, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'HEXA')),
            (111, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'HEXA')),
            (112, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (113, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (114, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (115, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (116, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (117, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (118, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (119, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (120, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (121, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (122, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (123, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (124, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (125, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (126, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (127, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (128, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (129, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (130, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (131, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (132, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (133, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (134, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (135, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (136, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO')),
            (137, (SELECT `id` FROM `prodlims`.`horizondisease` WHERE `cloudId` = 'TSCOMBO'));

            SET SQL_SAFE_UPDATES=1;
        </sql>
        <!-- Rollback: Table will be dropped if Horizon rolled back. -->
        <rollback/>
    </changeSet>
</databaseChangeLog>